Active substance
Carboplatin
- SFDA 12
- US FDA 39
- Health Canada 3
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CARBOPLATIN "EBEWE" 50MG-5ML | 10 mg/ml | Concentrate for solution for infusion · Parenteral use | 1 Vial | SAR 141.40 | Generic · Prescription | EBEWE PHARMA | Valid |
| CARBOPLATIN "EBEWE" 50MG-5ML | 10 mg/ml | Concentrate for solution for infusion · Parenteral use | 1 Vial | SAR 281.35 | Generic · Prescription | EBEWE PHARMA | Valid |
| CARBOPLATIN 10MG-ML VIAL | 10 mg/ml | Solution · Parenteral use | 1 Vial | SAR 141.40 | NCE · Prescription | HOSPIRA UK LIMITED | Valid |
| CARBOPLATIN 10MG-ML VIAL | 10 mg/ml | Solution · Parenteral use | 1 Vial | SAR 336.65 | NCE · Prescription | HOSPIRA UK LIMITED | Valid |
| CARTINUM 10 MG/ML VIAL | 10 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 242.20 | Generic · Prescription | Accord Healthcare Limited | Valid |
| CARTINUM 150 MG/15 ML | 10 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 127.25 | Generic · Prescription | Accord Healthcare Limited | Valid |
| CARBOPLATIN "EBEWE" 50MG-5ML | 10 mg/ml | Concentrate for solution for infusion · Parenteral use | 1 Vial | SAR 51.40 | Generic · Prescription | EBEWE PHARMA | Withdrawn by MAH · Not Marketed |
| CARBOPLATIN 10MG-ML VIAL | 10 mg/ml | Solution · Parenteral use | 1 Vial | SAR 446.55 | NCE · Prescription | HOSPIRA AUSTRALIA | Withdrawn by MAH · Not Marketed |
| CARBOPLATIN 10MG-ML VIAL | 10 mg/ml | Solution · Parenteral use | 1 Vial | SAR 194.50 | NCE · Prescription | HOSPIRA AUSTRALIA | Withdrawn by MAH · Not Marketed |
| CARBOTINOL 10MG/ML INJECTION | 10 mg/ml | Injection · Intravenous use | 1 Vial | SAR 293.30 | Generic · Prescription | EMIC UNITED PHARMACEUTICALS | Withdrawn by MAH · Not Marketed |
| KARBOTEEN 10 mg/ml Solution For IV Infusion | 10 mg/ml | Solution · Intravenous use | 1 Vial | SAR 102.85 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Withdrawn by MAH · Not Marketed |
| KARBOTEEN 10 mg/ml Solution For IV Infusion | 10 mg/ml | Solution · Intravenous use | 1 Vial | SAR 257.10 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ANAL CANCER; BLADDER CANCER; BONE SARCOMAS; BRAIN CANCERS; BREAST CANCER EARLY HER-2 -VE; BREAST CANCER HER-2 +VE; BREAST CANCER MET.HER-2 +VE; BREAST CANCER MET.HER-2 -VE; BURKITT`S LYMPHOMA; Cervical Cancer; DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); ENDOMETRIAL CANCER; ESOPHAGEAL CANCER; FOLLICULAR LYMPHOMA; GASTRIC CANCER; HEAD AND NECK CANCER; HODGKIN'S LYMPHOMA; MANTLE CELL LYMPHOMA; MESOTHELIOMA; Neuroblastoma; NEUROENDOCRINE TUMORS; Neurofibromatosis Type 1 - Optic Pathway Glioma; NON-SMALL-CELL LUNG CARCINOMA (NSCLC); OVARIAN CANCER; PEDIATRIC B-CELL LYMPHOMA; PROSTATE CANCER; RENAL CELL CARCINOMA (RCC)-COLLECTING DUCT, MEDULLARY NON-CC RCC; RETINOBLASTOMA; SMALL CELL LUNG CANCER (SCLC); SOFT TISSUE SARCOMA - RHABDOMYOSARCOMA; T-CELL LYMPHOMA; TESTICULAR CANCER; THYROID CANCER-ANAPLASTIC CARCINOMA; VAGINAL AND VULVAR CANCERS; WILMS TUMOR
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CARBOPLATIN | 50MG/5ML (10MG/ML); 150MG/15ML (10MG/ML); 450MG/45ML (10MG/ML) | injectable · intravenous | HOSPIRA | Prescription | 14 Oct 2004 |
| CARBOPLATIN | 50MG/5ML (10MG/ML); 150MG/15ML (10MG/ML); 450MG/45ML (10MG/ML); 600MG/60ML (10MG/ML) | injectable · intravenous | PHARMACHEMIE BV | Prescription | 14 Oct 2004 |
| CARBOPLATIN | 50MG/5ML (10MG/ML); 150MG/15ML (10MG/ML); 450MG/45ML (10MG/ML); 600MG/60ML (10MG/ML) | injectable · intravenous | HIKMA PHARMS | Prescription | 15 Oct 2004 |
| CARBOPLATIN | 600MG/60ML (10MG/ML) | injectable · intravenous | HOSPIRA | Prescription | 23 Nov 2004 |
| CARBOPLATIN | 450MG/45ML (10MG/ML); 600MG/60ML (10MG/ML) | injectable · intravenous | FRESENIUS KABI USA | Prescription | 15 Feb 2006 |
| CARBOPLATIN | 50MG/5ML (10MG/ML); 150MG/15ML (10MG/ML); 450MG/45ML (10MG/ML); 600MG/60ML (10MG/ML) | injectable · intravenous | TEYRO LABS | Prescription | 18 Jan 2007 |
| CARBOPLATIN | 50MG/5ML (10MG/ML); 150MG/15ML (10MG/ML); 450MG/45ML (10MG/ML) | injectable · intravenous | SANDOZ | Prescription | 8 May 2008 |
| CARBOPLATIN | 50MG/5ML (10MG/ML); 150MG/15ML (10MG/ML); 450MG/45ML (10MG/ML) | injectable · intravenous | SUN PHARM | Prescription | 19 Sep 2008 |
| CARBOPLATIN | 50MG/5ML (10MG/ML); 150MG/15ML (10MG/ML); 450MG/45ML (10MG/ML) | injectable · intravenous | EPIC PHARMA LLC | Prescription | 29 Jul 2009 |
| CARBOPLATIN | 600MG/60ML (10MG/ML) | injectable · intravenous | EPIC PHARMA LLC | Prescription | 28 Jul 2010 |
| CARBOPLATIN | 50MG/5ML (10MG/ML); 150MG/15ML (10MG/ML); 450MG/45ML (10MG/ML); 600MG/60ML (10MG/ML) | injectable · intravenous | EUGIA PHARMA | Prescription | 28 Mar 2016 |
| CARBOPLATIN | 50MG/5ML (10MG/ML); 150MG/15ML (10MG/ML); 450MG/45ML (10MG/ML); 600MG/60ML (10MG/ML); 1GM/100ML (10MG/ML) | injectable · intravenous | ACCORD HLTHCARE | Prescription | 9 Feb 2017 |
| CARBOPLATIN | 50MG/5ML (10MG/ML); 150MG/15ML (10MG/ML); 450MG/45ML (10MG/ML); 600MG/60ML (10MG/ML) | injectable · intravenous | GLAND | Prescription | 15 Feb 2017 |
| KYXATA | 80MG/8ML (10MG/ML); 500MG/50ML (10MG/ML) | solution · intravenous | AVYXA HOLDINGS | Prescription | 8 Aug 2025 |
| PARAPLATIN | 50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 150MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 450MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | CORDEN PHARMA | Discontinued | 3 Mar 1989 |
| PARAPLATIN | 50MG/5ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 150MG/15ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 450MG/45ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 600MG/60ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · intravenous | CORDENPHARMA | Discontinued | 14 Jul 2003 |
| CARBOPLATIN | 50MG/VIAL; 150MG/VIAL; 450MG/VIAL | injectable · injection | HIKMA PHARMS | Discontinued | 14 Oct 2004 |
| CARBOPLATIN | 50MG/VIAL; 150MG/VIAL; 450MG/VIAL | injectable · injection | WATSON LABS TEVA | Discontinued | 14 Oct 2004 |
| CARBOPLATIN | 50MG/VIAL; 150MG/VIAL; 450MG/VIAL | injectable · injection | FRESENIUS KABI USA | Discontinued | 14 Oct 2004 |
| CARBOPLATIN | 50MG/5ML (10MG/ML); 150MG/15ML (10MG/ML); 450MG/45ML (10MG/ML) | injectable · intravenous | FRESENIUS KABI USA | Discontinued | 21 Oct 2004 |
| CARBOPLATIN | 50MG/VIAL; 150MG/VIAL; 450MG/VIAL | injectable · injection | HOSPIRA | Discontinued | 27 Oct 2004 |
| CARBOPLATIN | 50MG/VIAL; 150MG/VIAL; 450MG/VIAL | injectable · injection | PLIVA | Discontinued | 16 Nov 2004 |
| CARBOPLATIN | 50MG/VIAL; 150MG/VIAL; 450MG/VIAL | injectable · injection | SANDOZ | Discontinued | 18 Mar 2005 |
| CARBOPLATIN | 50MG/5ML (10MG/ML); 150MG/15ML (10MG/ML); 450MG/45ML (10MG/ML); 600MG/60ML (10MG/ML) | injectable · intravenous | MEITHEAL | Discontinued | 14 Jun 2005 |
| CARBOPLATIN | 50MG/5ML (10MG/ML); 150MG/15ML (10MG/ML); 450MG/45ML (10MG/ML); 600MG/60ML (10MG/ML) | injectable · intravenous | TEVA PHARMS USA | Discontinued | 21 Sep 2005 |
14 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CARBOPLATIN INJECTION | 02125439 | 10 MG / ML | SOLUTION · INTRAVENOUS | TEVA CANADA LIMITED |
| CARBOPLATIN INJECTION BP | 02126680 | 10 MG / ML | SOLUTION · INTRAVENOUS | PFIZER CANADA ULC |
| CARBOPLATIN INJECTION BP | 02320371 | 10 MG / ML | SOLUTION · INTRAVENOUS | ACCORD HEALTHCARE INC |
WHO WHO Model List of Essential Medicines (2025)
- 8.2.1. Cytotoxic medicines · complementary
Other specified gliomas of brain; Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx; Malignant neoplasms of cervix uteri; Malignant neoplasms of hypopharynx; Malignant neoplasms of nasopharynx; Malignant neoplasms of oropharynx; Osteosarcoma of bone or articular cartilage of unspecified sites; Other specified malignant neoplasms of the ovary; Germ cell tumour of testis; Other specified carcinomas of ovary; Other specified malignant neoplasms of bronchus or lung; Malignant neoplasms of breast; Retinoblastoma; Malignant neoplasms of kidney, except renal pelvis
Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.